Information Provided By:
Fly News Breaks for April 11, 2019
ARQL
Apr 11, 2019 | 07:27 EDT
RBC Capital analyst Gregory Renza initiated ArQule with an Outperform rating and a price target of $9. The analyst is positive on the company's "unique clinical portfolio of precision-based kinase inhibitors in oncology and orphan disease." Renza also expects that portfolio to appreciate over the year with additional clinical data for ARQ '531 inhibitor and progress on miransertib further de-risking the investment story.
News For ARQL From the Last 2 Days
There are no results for your query ARQL